Back to search

Article

Clinical Development of Molecular Residual Disease (MRD) and Multi-Cancer Early Detection (MCED) using Liquid Biopsy Multiomics with Artificial Intelligence (AI)

2025-12-06

Abstract excerpt

<title>Abstract</title> <p>Background Early detection of cancer and precise recurrence monitoring remain major unmet needs in oncology. Conventional screening is limited to a few cancer types, leaving nearly half of cancers without established programs. Multi-cancer early detection (MCED) tests based on circulating tumor biomarkers have shown promise, but sensitivity for early-stage remains a challenge. In parall...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
bf7f43c6-07bb-5924-89e4-afc72d3caa85
DOI
10.21203/rs.3.rs-8176801/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Clinical Development of Molecular Residual Disease (MRD) and Multi-Cancer Early Detection (MCED) using Liquid Biopsy Multiomics with Artificial Intelligence (AI)DOI 10.21203/rs.3.rs-8176801/v1
AI enabled exome and transcriptome liquid biopsy platform spanning the continuum of care in oncologySemantic proximity
Validation of an AI-enabled exome/transcriptome liquid biopsy platform for early detection, MRD, disease monitoring, and therapy selection for solid tumorsSemantic proximity
Bridging Discovery and Treatment: Cancer BiomarkerSemantic proximity
Integrating artificial intelligence with circulating tumor DNA for non-small cell lung cancer: opportunities, challenges, and future directionsSemantic proximity
Emerging technologies for improved stratification of cancer patients: a review of opportunities, challenges, and tools.Semantic proximity
Molecular residual disease assessment based on tumor-informed assay predict disease progression and postoperative recurrence of hepatobiliary cancer: A preliminary studySemantic proximity
AI-driven biomarker discovery: enhancing precision in cancer diagnosis and prognosisSemantic proximity
Analytical validation and clinical utilization of K-4CARE<sup>TM</sup>: a comprehensive genomic profiling assay with personalized MRD detectionSemantic proximity
Performance of a multi-target, multi-cancer early detection (MCED) blood test in a prospectively collected cohortSemantic proximity
Performance of Liquid Biopsy‐Based Multi‐Omics Biomarkers for Early Detection of Gynecological Malignancies: A Prospective Study (PERCEIVE‐I)Semantic proximity
Minimal Residual Disease in Oncology: From Cure to Longitudinal Patient ManagementSemantic proximity
Bridging horizons beyond CIRCULATE-Japan: a new paradigm in molecular residual disease detection via whole genome sequencing-based circulating tumor DNA assaySemantic proximity
Select a neighboring publication to make it the new centre.